NCT01177098 - Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Biotech Hunter

Enrollment

561

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions

GlaucomaOcular Hypertension

Interventions

DRUG

bimatoprost /timolol formulation A fixed combination ophthalmic solution

One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.

DRUG

bimatoprost/timolol fixed combination ophthalmic solution

One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.

Trial Locations (9)

Artesia

Sydney

Brno

Leipzig

Budapest

Tel Aviv

Saint Petersburg

Valencia

London